ClinicalTrials.gg
RecruitingNCT07074444Updated Oct 1, 2026

Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel

An interventional study of Albendazole and Tribendimidine in Clonorchiasis, sponsored by First Affiliated Hospital of Guangxi Medical University. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by First Affiliated Hospital of Guangxi Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Oct 1, 2026Site recruiting status changedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
318
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate and compare the efficacy and safety of three commonly used antiparasitic drugs-albendazole, tribendimidine, and praziquantel-for the treatment of clonorchiasis, a liver fluke infection acquired by consuming raw or undercooked freshwater fish.

This study aims to answer the following primary questions:

How effective is each drug in achieving parasitological cure, as measured by clearance of Clonorchis sinensis eggs in stool? What types and frequencies of adverse events are associated with each treatment?

Participants in this randomized, open-label trial will:

Be randomly assigned to receive one of the three study drugs according to a predefined dosing regimen.

Provide stool samples before treatment and at follow-up to assess for Clonorchis sinensis eggs.

Undergo a second round of the same treatment regimen and repeated stool examination if eggs are still detected after the first course.

Attend follow-up visits, which include symptom assessment and blood tests (hematology and liver function).

Report any side effects, discomfort, or adverse reactions experienced during or after treatment.

The findings from this study will help inform optimal therapeutic strategies for clonorchiasis in outpatient clinical settings.

02

Conditions studied

  • Clonorchiasis

Keywords

  • Clonorchiasis
  • Albendazole
  • Praziquantel
  • Egg clearance rate
  • tribendimidine
03

In context

Lead sponsor

First Affiliated Hospital of Guangxi Medical University is the lead sponsor of 42 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged ≥18 years.
  2. Confirmed diagnosis of Clonorchis sinensis infection based on the latest Expert Consensus on Diagnosis and Treatment of Food-Borne Parasitic Diseases (2023): detection of eggs or adult worms in stool or bile drainage fluid.
  3. Willing and able to provide written and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Known or allergy to albendazole, praziquantel, or tribendimidine.
  2. (ECG)-confirmed supraventricular tachycardia or atrial fibrillation.
  3. Clinically or radiologically diagnosed neurocysticercosis (brain or spinal cord) or ocular cysticercosis (eye or orbit).
  4. Presence of gallbladder stones or biliary tract obstruction as confirmed by abdominal ultrasound.
  5. Individuals with severe hepatic, renal, or cardiac dysfunction, or with active peptic ulcer disease.
  6. Pregnant or breastfeeding individuals, or those of (male or female) who are unwilling to use effective during the study period and for 3 months following the last dose of study medication.
  7. Anticipated loss to follow-up due to relocation, withdrawal of consent, or other factors affecting adherence to the study protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
318 participants (estimated)

Study arms

  • Active comparator
    Praziquantel

    Praziquantel tablets: Administer orally at 25 mg/kg per dose, three times daily (TID) for 2 consecutive days. The dose will be adjusted based on the participant's body weight. If the calculated dose results in a non-integer number of tablets, the dose will be adjusted to the nearest whole tablet according to the physician's recommendation.

    Drug: praziquantel

  • Experimental
    Albendazole

    Albendazole tablets: Administer orally at 10 mg/kg/day for 7 consecutive days. The daily dose will be administered in two divided doses. The dose will be adjusted based on the participant's body weight. If the calculated dose results in a non-integer number of tablets, the actual dose may be adjusted to the nearest whole tablet. The specific dose will be adjusted according to the physician's recommendation.

    Drug: Albendazole

  • Experimental
    Tribendimidine

    Tribendimidine enteric-coated tablets: Administer orally at 0.4 g once daily (QD) for 3 consecutive days.

    Drug: Tribendimidine

Interventions

  • Participants receive albendazole tablets orally at a total daily dose of 10 mg/kg for 7 consecutive days. The daily dose will be administered in two divided doses. If the calculated dose results in a non-integer number of tablets, the dose will be adjusted to the nearest whole tablet as per the physician's recommendation.

  • DrugTribendimidine

    Patients receive tribendimidine enteric-coated tablets orally at 0.4 g once daily (QD) for 3 consecutive days.

  • Participants receive praziquantel tablets orally at 25 mg/kg per dose, three times daily (TID) for 2 consecutive days. If the calculated dose results in a non-integer number of tablets, the dose will be adjusted to the nearest whole tablet as per the physician's recommendation.

06

What researchers measure

Primary outcomes

  1. Egg Clearance Rate

    The primary outcome is the proportion of participants who test negative for Clonorchis sinensis eggs in at least one stool sample collected 4 weeks after treatment.

    Time frame: From 4 weeks to 4 months after the last dose of treatment

Secondary outcomes

  1. Symptom Improvement Rate

    Symptom improvement will be assessed using a standardized symptom questionnaire or physician-recorded clinical evaluation. Typical symptoms associated with clonorchiasis-such as right upper abdominal pain, fatigue, and diarrhea-will be documented at baseline and again at the Week 4 follow-up visit. A symptom is considered improved if its severity score decreases by at least 50% or if it has completely resolved by that follow-up visit.

    Time frame: Baseline and Week 4 after the last dose of treatment

  2. Adverse Events (AEs)

    Adverse events (AEs) will be collected from the initiation of treatment until the first follow-up visit. All events will be graded according to CTCAE version 5.0, and causality will be assessed using a five-level scale (definitely, probably, possibly, possibly not, and definitely not related). Serious adverse events (SAEs) will be documented and reported separately.

    Time frame: Baseline and Week 4 after the last dose of treatment

  3. Proportion of Abnormal Hematology and Liver Function Results

    Venous blood samples will be collected at baseline and follow-up for hematology and liver function tests. An abnormal result is defined as any value exceeding the laboratory reference range or deemed clinically significant by the investigator.

    Time frame: Baseline and Week 4 after the last dose of treatment

  4. Drug Intolerance Rate

    Drug intolerance is defined as the inability to complete the planned treatment regimen due to serious adverse reactions, interruption of medication, or participant refusal. Data will be collected via participant self-report and investigator inquiry at the follow-up visit.

    Time frame: From first dose to Day 31 (+1 day) after the last dose of treatment

Other outcomes

  1. Egg Clearance Rate After Second Treatment

    Among participants who remain egg-positive after the first treatment, a second course of the same antiparasitic regimen will be administered. Stool examinations will be performed 4 weeks after the second treatment.

    Time frame: Week 4 after the last dose of second treatment

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 6 months after publication, available upon request for 3 years.

Access criteria: Researchers can gain access to the individual participant data (IPD) and supporting information by submitting a data sharing request proposal. The proposal must include a description of the planned analyses, including the statistical methods to be used. Proposals will be reviewed by an independent data access committee to ensure that the analyses are aligned with the study's objectives and meet ethical and scientific standards. To gain access, researchers must sign a data sharing agreement, which outlines the terms of use, including the intended use of the data, and any conditions for publication of results. Data sharing requests will be reviewed on a rolling basis, and researchers will be notified of the decision within 60 days of submission.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2025 (actual). Primary completion is estimated for Feb 2027, 19 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Nov 2026 → Feb 2027 and completion Dec 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
Jul 20, 2025
StartActual
Jul 22, 2025
Primary completionEst.
Feb 28, 2027was Nov 2026
CompletionEst.
Feb 28, 2027was Dec 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
People's Hospital of Guangxi Zhuang Autonomous Region is now Recruiting
Oct 1, 2026
Primary completion
Nov 30, 2026→Feb 28, 2027
Oct 1, 2026
Study completion
Dec 31, 2026→Feb 28, 2027
Oct 1, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameEgg Clearance RateFrom Day 30 to Day 60 after the last dose of treatment → From 4 weeks to 4 months after the last dose of treatment
  • DescriptionEgg Clearance Rate: how it is measured was reworded
Oct 1, 2026
Secondary outcomes
4 time frame changed, 1 removed, 4 description edited
What changed in the outcomes
  • RemovedHepatobiliary Ultrasonographic ImprovementTime frame: Baseline and Day 31 (±1 day) after the last dose of treatment
  • Time frameSymptom Improvement RateBaseline and Day 31 (±1 day) after the last dose of treatment → Baseline and Week 4 after the last dose of treatment
  • Time frameAdverse Events (AEs)From first dose to Day 30 (±1day) after the last dose of treatment → Baseline and Week 4 after the last dose of treatment
  • Time frameProportion of Abnormal Hematology and Liver Function ResultsBaseline and Day 31(±1 day) after the last dose of treatment → Baseline and Week 4 after the last dose of treatment
  • DescriptionAdverse Events (AEs): how it is measured was reworded
  • DescriptionProportion of Abnormal Hematology and Liver Function Results: how it is measured was reworded
  • DescriptionSymptom Improvement Rate: how it is measured was reworded
  • Time frameother outcomeEgg Clearance Rate After Second TreatmentFrom Day 30 to Day 60 after the last dose of second treatment] → Week 4 after the last dose of second treatment
  • Descriptionother outcomeEgg Clearance Rate After Second Treatment: how it is measured was reworded
Oct 1, 2026
Design
Phase 4→Not applicable
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    People's Hospital of Guangxi Zhuang Autonomous Region is now Recruiting
    Primary completion Nov 30, 2026→Feb 28, 2027
    Study completion Dec 31, 2026→Feb 28, 2027
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameEgg Clearance RateFrom Day 30 to Day 60 after the last dose of treatment → From 4 weeks to 4 months after the last dose of treatment
    • DescriptionEgg Clearance Rate: how it is measured was reworded
    Secondary outcomes 4 time frame changed, 1 removed, 4 description edited
    What changed in the outcomes
    • RemovedHepatobiliary Ultrasonographic ImprovementTime frame: Baseline and Day 31 (±1 day) after the last dose of treatment
    • Time frameSymptom Improvement RateBaseline and Day 31 (±1 day) after the last dose of treatment → Baseline and Week 4 after the last dose of treatment
    • Time frameAdverse Events (AEs)From first dose to Day 30 (±1day) after the last dose of treatment → Baseline and Week 4 after the last dose of treatment
    • Time frameProportion of Abnormal Hematology and Liver Function ResultsBaseline and Day 31(±1 day) after the last dose of treatment → Baseline and Week 4 after the last dose of treatment
    • DescriptionAdverse Events (AEs): how it is measured was reworded
    • DescriptionProportion of Abnormal Hematology and Liver Function Results: how it is measured was reworded
    • DescriptionSymptom Improvement Rate: how it is measured was reworded
    • Time frameother outcomeEgg Clearance Rate After Second TreatmentFrom Day 30 to Day 60 after the last dose of second treatment] → Week 4 after the last dose of second treatment
    • Descriptionother outcomeEgg Clearance Rate After Second Treatment: how it is measured was reworded
    Design Phase 4→Not applicable
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07074444
Lead sponsor
First Affiliated Hospital of Guangxi Medical University
Collaborators
People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Jul 22, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Hongliang Zhang
Contact
277749097@qq.com
+86 13737143253
Hongliang Zhang
principal investigator · First Affiliated Hospital of Guangxi Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albendazole

Start the discussion